N
News Analysis
dailypolitical.com

www.dailypolitical.com ·

Neutral

Inhibitor Therapeutics Otcmktsinti Posts Quarterly Earnings Results

Basal Cell CarcinomaAnalystPrivate Sector DevelopmentBusiness Climate

All NewsRead the full story on dailypolitical.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

The article reports quarterly earnings for a small-cap biotech firm with no material commercial mechanism. No revenue, product sales, or operational changes are disclosed. The company's stock is thinly traded and the earnings figure appears anomalous (likely a data error). No supply chain, pricing, or regulatory impact is evident. The commercial pathway is absent.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Inhibitor Therapeutics (OTCMKTS:INTI) reported EPS of $999.00 for the quarter.
  • Stock price remained flat at $0.08 with volume of 15,477 shares.
  • Market capitalization is $14.35 million; 52-week range $0.03-$0.12.
  • Company focuses on therapeutics for certain cancers; positive Phase 2b trial for basal cell carcinoma nevus syndrome.
  • Formerly HedgePath Pharmaceuticals, rebranded in August 2019.

About the publisher

dailypolitical.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

dailypolitical.com files this story under "basal cell carcinoma" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

Inhibitor Therapeutics Otcmktsinti Posts Quarterly Earnings Results — News Analysis